Testing microRNA markers to spot newborn opioid withdrawal
Part of Genetic & congenital, Mental health clinical trials.
This study looks at tiny genetic signals (microRNA) in newborn samples to identify neonatal opioid withdrawal syndrome. It may help doctors recognize withdrawal sooner, so babies can get the right care faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby was born at or transferred to Penn State Hershey Medical Center within 48 hours
- Baby was born at 35 weeks or later (not preterm)
- Baby had long-term exposure to opioids before birth (about more than 1 month)
- There was ongoing opioid use by the birth parent during pregnancy (about more than 1 month)
- Baby must not need breathing support like a ventilator or noninvasive mechanical support
- Parents/guardians can provide consent, and baby has no major birth defects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to improve care for mothers with opioid use disorder and their babies with neonatal abstinence syndrome. Researchers will interview healthcare providers and mothers to develop better support programs.
This study looks at different medicine approaches to treat newborns with opioid withdrawal (NOWS). It compares how well babies do with standard care and may help find the best way to manage symptoms and support recovery.
This study looks at how opioid exposure during pregnancy affects blood flow and brain function in newborns. Researchers will compare babies exposed to opioids in the womb with babies who were not exposed, to better understand how prenatal opioid exposure affects the developing brain.
This program helps participating hospitals improve care for newborns who may go through opioid withdrawal (also called neonatal abstinence syndrome). It mainly aims to make mother-baby support and treatment plans work better after delivery.
This study is collecting information from two groups of newborns: those with Neonatal Abstinence Syndrome (NAS, caused by drug exposure before birth) and healthy newborns. The goal is to see if an automated system makes it easier to gather data without extra tests or procedures.
This study aims to better understand how people experience opioid withdrawal. You will be asked to describe your symptoms, which may help develop a new tool to measure withdrawal more accurately.
Hear when a new Neonatal Opioid Withdrawal Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.